A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper regimen in patients with giant cell arteritis (GCA) (GCAptAIN) | NYU Langone Health

Go Back to All Clinical Trials

A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper regimen in patients with giant cell arteritis (GCA) (GCAptAIN)